Abstract
Abstract Analytical methodology has been developed to assay L-660, 711, 3-(((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)((3-dimethylamino-3-oxopropyl)thio)methyl)thio)propionic acid to assess drug stability in pharmaceutical preparations and drug concentration in plasma samples. Reversed-phase HPLC chromatography with UV detection at 232 nm and 300 nm was used to analyze drug content and assess stability in pharmaceutical formulations. In addition to UV, fluorescence detection with 300 nm and 400 nm as the excitation-emission wavelength pair was used to enhance sensitivity for biological samples with low drug concentrations. The latter system had a detection limit of 1–5 ng/ml for a 25 μl injection. It was used to monitor drug concentration in plasma following intrapulmonary, intravenous and oral administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
